D. El-Ghaffar, Amal AF Halim, E. Abdallah, Doaa A Sharaf, S. Yussif
{"title":"雄激素受体和细胞周期蛋白D1在乳腺浸润导管癌中的预后价值","authors":"D. El-Ghaffar, Amal AF Halim, E. Abdallah, Doaa A Sharaf, S. Yussif","doi":"10.58775/2735-3990.1387","DOIUrl":null,"url":null,"abstract":"Objective : Breast cancer (BC) tissue is heterogeneous with a number of cellular pathways involved in cell growth and proliferation. Activation of androgen receptors (AR) signaling pathways plays a role in BC. On the other hand, cyclin is a regulatory subunit of cyclin-dependent kinases that affect cell cycle G1/S transition. This study aimed at investigating the relationship between the expression of AR and cyclin D1 and the clinicopathological details of BC patients registered in the archive of our department within a speci fi ed period and determining the prognostic impact of such expression. Methods : The study included 182 IDC patients aged from 20 to 65 whom were registered in the archive of the Clinical Oncology & Nuclear Medicine Department from January 2013 to December 2015. All clinicopathological data were obtained from patient records. Immunohistochemistry study for AR and cyclin D1 was done for the pathologic specimens. Results : The expression ratio of AR in 182 specimens was 43.4% (79/182). AR positivity was signi fi cantly associated with estrogen receptor (ER) and progesterone receptor (PR) positivity and negative HER2 status, lower tumor grade, smaller tumor size, and negative lymph node involvement ( P values < 0.05). Cyclin D1 positivity was reported in 116/182 (64%). There was positive correlation between cyclin D1 and ER, PR positivity, triple negativity, small tumor size, and negative lymph node involvement ( P value < 0.05). The","PeriodicalId":18173,"journal":{"name":"Mansoura Veterinary Medical Journal","volume":"34 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The prognostic value of androgen receptor and cyclin D1 in infiltrating duct carcinoma of the breast\",\"authors\":\"D. El-Ghaffar, Amal AF Halim, E. Abdallah, Doaa A Sharaf, S. Yussif\",\"doi\":\"10.58775/2735-3990.1387\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective : Breast cancer (BC) tissue is heterogeneous with a number of cellular pathways involved in cell growth and proliferation. Activation of androgen receptors (AR) signaling pathways plays a role in BC. On the other hand, cyclin is a regulatory subunit of cyclin-dependent kinases that affect cell cycle G1/S transition. This study aimed at investigating the relationship between the expression of AR and cyclin D1 and the clinicopathological details of BC patients registered in the archive of our department within a speci fi ed period and determining the prognostic impact of such expression. Methods : The study included 182 IDC patients aged from 20 to 65 whom were registered in the archive of the Clinical Oncology & Nuclear Medicine Department from January 2013 to December 2015. All clinicopathological data were obtained from patient records. Immunohistochemistry study for AR and cyclin D1 was done for the pathologic specimens. Results : The expression ratio of AR in 182 specimens was 43.4% (79/182). AR positivity was signi fi cantly associated with estrogen receptor (ER) and progesterone receptor (PR) positivity and negative HER2 status, lower tumor grade, smaller tumor size, and negative lymph node involvement ( P values < 0.05). Cyclin D1 positivity was reported in 116/182 (64%). There was positive correlation between cyclin D1 and ER, PR positivity, triple negativity, small tumor size, and negative lymph node involvement ( P value < 0.05). The\",\"PeriodicalId\":18173,\"journal\":{\"name\":\"Mansoura Veterinary Medical Journal\",\"volume\":\"34 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mansoura Veterinary Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.58775/2735-3990.1387\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mansoura Veterinary Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58775/2735-3990.1387","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The prognostic value of androgen receptor and cyclin D1 in infiltrating duct carcinoma of the breast
Objective : Breast cancer (BC) tissue is heterogeneous with a number of cellular pathways involved in cell growth and proliferation. Activation of androgen receptors (AR) signaling pathways plays a role in BC. On the other hand, cyclin is a regulatory subunit of cyclin-dependent kinases that affect cell cycle G1/S transition. This study aimed at investigating the relationship between the expression of AR and cyclin D1 and the clinicopathological details of BC patients registered in the archive of our department within a speci fi ed period and determining the prognostic impact of such expression. Methods : The study included 182 IDC patients aged from 20 to 65 whom were registered in the archive of the Clinical Oncology & Nuclear Medicine Department from January 2013 to December 2015. All clinicopathological data were obtained from patient records. Immunohistochemistry study for AR and cyclin D1 was done for the pathologic specimens. Results : The expression ratio of AR in 182 specimens was 43.4% (79/182). AR positivity was signi fi cantly associated with estrogen receptor (ER) and progesterone receptor (PR) positivity and negative HER2 status, lower tumor grade, smaller tumor size, and negative lymph node involvement ( P values < 0.05). Cyclin D1 positivity was reported in 116/182 (64%). There was positive correlation between cyclin D1 and ER, PR positivity, triple negativity, small tumor size, and negative lymph node involvement ( P value < 0.05). The